2022
DOI: 10.5469/neuroint.2021.00458
|View full text |Cite
|
Sign up to set email alerts
|

Subsequent Subarachnoid Hemorrhage from Clinically Unrelated Vertebral Artery Dissection after Thrombolytic Therapy

Abstract: Thrombolysis administration poses certain safety issues in ischemic stroke patients with cerebrovascular changes that are vulnerable to hemorrhage. Furthermore, the lack of related studies has resulted in an unclear understanding of thrombolysis safety in ischemic stroke patients with intracranial dissection, including those involving the vertebral artery. This study describes a case of a 59-year-old female who developed subarachnoid hemorrhage from clinically unrelated vertebral artery dissection after thromb… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 19 publications
0
1
0
Order By: Relevance
“…Ultra‐early arterial thrombolysis and mechanical embolization are considered to be the most effective treatments for AIS; however, patients often miss treatment opportunities owing to missed treatment windows or comorbidities (Jolugbo & Ariens, 2021; Menon et al, 2018; Moussaddy et al, 2018). At the same time, the safety of thrombolysis and mechanical thrombolysis treatment is also problematic (Bae & Ha, 2022; Balami et al, 2018); therefore, in clinical practice, the use of anticoagulants, fibrin modulators and antiplatelet agents alone or in combination with neuroprotective drugs is still the main therapy used for the prevention and treatment of different types of secondary brain injury (Wu et al, 2020).…”
Section: Introductionmentioning
confidence: 99%
“…Ultra‐early arterial thrombolysis and mechanical embolization are considered to be the most effective treatments for AIS; however, patients often miss treatment opportunities owing to missed treatment windows or comorbidities (Jolugbo & Ariens, 2021; Menon et al, 2018; Moussaddy et al, 2018). At the same time, the safety of thrombolysis and mechanical thrombolysis treatment is also problematic (Bae & Ha, 2022; Balami et al, 2018); therefore, in clinical practice, the use of anticoagulants, fibrin modulators and antiplatelet agents alone or in combination with neuroprotective drugs is still the main therapy used for the prevention and treatment of different types of secondary brain injury (Wu et al, 2020).…”
Section: Introductionmentioning
confidence: 99%